4CPS-057 Discontinuation of proton pump inhibitors during hospitalisation: a randomised controlled trial

Background and importanceMany patients take proton pump inhibitors (PPIs) even though the drugs are no longer needed.1 2 We know that there are side effects to long-term PPI treatment.3 No previous studies have examined whether it is possible to reduce or discontinue treatment during hospitalisation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2022-03, Vol.29 (Suppl 1), p.A46-A47
Hauptverfasser: Nielsen, JL, Sørensen, CA, Stawowy, M, Bonnerup, DK
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A47
container_issue Suppl 1
container_start_page A46
container_title European journal of hospital pharmacy. Science and practice
container_volume 29
creator Nielsen, JL
Sørensen, CA
Stawowy, M
Bonnerup, DK
description Background and importanceMany patients take proton pump inhibitors (PPIs) even though the drugs are no longer needed.1 2 We know that there are side effects to long-term PPI treatment.3 No previous studies have examined whether it is possible to reduce or discontinue treatment during hospitalisation and continue it successfully after discharge.Aim and objectivesThe aim of the study was to investigate if PPIs can be discontinued or reduced through counselling by pharmacy staff during hospitalisation.Material and methodsA prospective randomised controlled study was performed in the Emergency and Medical Department. Patients were included if they had received PPIs for at least 2 months and were aged 18 years or older.Patients were excluded(1) if they were diagnosed with gastric ulcer within 6 months, eosinophilic oesophagitis, gastroesophageal reflux disease (GERD), Barrett’s oesophagus, gastrinoma and (2) if they were aged over 50 years and on treatment with non-steroidal anti-inflammatory drug (NSAIDs) except low-dose acetylsalicylic acid, steroids and/or platelet inhibitors, anticoagulants.The intervention was performed by pharmacy staff and included counselling on discontinuation or reduction of the use of PPIs, and also included a strategy to cope with rebound symptoms.The primary outcome was the proportion of patients who successfully discontinued or reduced their use of PPIs at follow-up telephone call 30 days after discharge. The data were tested with Fisher’s exact test (small samples).Results31 adults were included; 4 withdrew at their own request or because they could not be reached on follow-up telephone calls. 69.2% (95% CI 38.6% to 90.9%) (9/13 patients) in the intervention group successfully discontinued or reduced their PPI compared to 7.1% (95% CI 0.2 to 33.9) (1/14 patients) in the control group. The difference between groups was statistically significant (p=0.001).Conclusion and relevanceStatistically significantly more patients discontinued or reduced their use of PPI after counselling by the pharmacy staff. The pharmacy staff is capable of identifying patients for whom PPI dose reduction or discontinuation is relevant and performing a successful counselling on discontinuation or reduction of the use of PPIs.References and/or acknowledgements1. Schepisi R, et al. J Nutr Health Aging 2016;20(6):665–670.2. Akram F, et al. Australas Med J 2014;7(11):465–470.3. Mössner, J. Dtsch Arztebl Int 2016;113:477–483.Conflict of interestNo conflict of i
doi_str_mv 10.1136/ejhpharm-2022-eahp.98
format Article
fullrecord <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2672361853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2672361853</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1178-fde5a67ad8c3025bc637154a4f6c47f3f68bf6b510512272453d3071aad5a5f73</originalsourceid><addsrcrecordid>eNpFkEtLxDAUhYMoONT5CULAdce8k7qT8QkDCuq6pI_YlLapSbp34x_1l9g6Plb3LM49954PgFOMNhhTcV63zdho36cEEZLWuhk3mToAK4KYTLNMsMM_zcUxWIdgC8QpVRmj2Qq0bPv4lCIuP98_rmwo3RDtMOlo3QCdgaN3cVbj1I_QDo0tbHQ-wGrydniFjQujjbqz4XvhAmro9VC53oa6gkuWd103y-it7k7AkdFdqNc_MwEvN9fP27t093B7v73cpQXGUqWmqrkWUleqpIjwohRUYs40M6Jk0lAjVGFEwTHimBBJGKcVRRJrXXHNjaQJONvnzs-_TXWIeesmP8wncyIkoQKruX8C8N5V9O2_AaN8oZr_Us0XqvlCNc8U_QLBHHBZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2672361853</pqid></control><display><type>article</type><title>4CPS-057 Discontinuation of proton pump inhibitors during hospitalisation: a randomised controlled trial</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Nielsen, JL ; Sørensen, CA ; Stawowy, M ; Bonnerup, DK</creator><creatorcontrib>Nielsen, JL ; Sørensen, CA ; Stawowy, M ; Bonnerup, DK</creatorcontrib><description>Background and importanceMany patients take proton pump inhibitors (PPIs) even though the drugs are no longer needed.1 2 We know that there are side effects to long-term PPI treatment.3 No previous studies have examined whether it is possible to reduce or discontinue treatment during hospitalisation and continue it successfully after discharge.Aim and objectivesThe aim of the study was to investigate if PPIs can be discontinued or reduced through counselling by pharmacy staff during hospitalisation.Material and methodsA prospective randomised controlled study was performed in the Emergency and Medical Department. Patients were included if they had received PPIs for at least 2 months and were aged 18 years or older.Patients were excluded(1) if they were diagnosed with gastric ulcer within 6 months, eosinophilic oesophagitis, gastroesophageal reflux disease (GERD), Barrett’s oesophagus, gastrinoma and (2) if they were aged over 50 years and on treatment with non-steroidal anti-inflammatory drug (NSAIDs) except low-dose acetylsalicylic acid, steroids and/or platelet inhibitors, anticoagulants.The intervention was performed by pharmacy staff and included counselling on discontinuation or reduction of the use of PPIs, and also included a strategy to cope with rebound symptoms.The primary outcome was the proportion of patients who successfully discontinued or reduced their use of PPIs at follow-up telephone call 30 days after discharge. The data were tested with Fisher’s exact test (small samples).Results31 adults were included; 4 withdrew at their own request or because they could not be reached on follow-up telephone calls. 69.2% (95% CI 38.6% to 90.9%) (9/13 patients) in the intervention group successfully discontinued or reduced their PPI compared to 7.1% (95% CI 0.2 to 33.9) (1/14 patients) in the control group. The difference between groups was statistically significant (p=0.001).Conclusion and relevanceStatistically significantly more patients discontinued or reduced their use of PPI after counselling by the pharmacy staff. The pharmacy staff is capable of identifying patients for whom PPI dose reduction or discontinuation is relevant and performing a successful counselling on discontinuation or reduction of the use of PPIs.References and/or acknowledgements1. Schepisi R, et al. J Nutr Health Aging 2016;20(6):665–670.2. Akram F, et al. Australas Med J 2014;7(11):465–470.3. Mössner, J. Dtsch Arztebl Int 2016;113:477–483.Conflict of interestNo conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2022-eahp.98</identifier><language>eng</language><publisher>London: British Medical Journal Publishing Group</publisher><subject>Conflicts of interest ; Counseling ; Gastroesophageal reflux ; Hospitalization ; Neuroendocrine tumors ; Pharmacy ; Section 4: Clinical pharmacy services</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2022-03, Vol.29 (Suppl 1), p.A46-A47</ispartof><rights>European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2022 European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Nielsen, JL</creatorcontrib><creatorcontrib>Sørensen, CA</creatorcontrib><creatorcontrib>Stawowy, M</creatorcontrib><creatorcontrib>Bonnerup, DK</creatorcontrib><title>4CPS-057 Discontinuation of proton pump inhibitors during hospitalisation: a randomised controlled trial</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><description>Background and importanceMany patients take proton pump inhibitors (PPIs) even though the drugs are no longer needed.1 2 We know that there are side effects to long-term PPI treatment.3 No previous studies have examined whether it is possible to reduce or discontinue treatment during hospitalisation and continue it successfully after discharge.Aim and objectivesThe aim of the study was to investigate if PPIs can be discontinued or reduced through counselling by pharmacy staff during hospitalisation.Material and methodsA prospective randomised controlled study was performed in the Emergency and Medical Department. Patients were included if they had received PPIs for at least 2 months and were aged 18 years or older.Patients were excluded(1) if they were diagnosed with gastric ulcer within 6 months, eosinophilic oesophagitis, gastroesophageal reflux disease (GERD), Barrett’s oesophagus, gastrinoma and (2) if they were aged over 50 years and on treatment with non-steroidal anti-inflammatory drug (NSAIDs) except low-dose acetylsalicylic acid, steroids and/or platelet inhibitors, anticoagulants.The intervention was performed by pharmacy staff and included counselling on discontinuation or reduction of the use of PPIs, and also included a strategy to cope with rebound symptoms.The primary outcome was the proportion of patients who successfully discontinued or reduced their use of PPIs at follow-up telephone call 30 days after discharge. The data were tested with Fisher’s exact test (small samples).Results31 adults were included; 4 withdrew at their own request or because they could not be reached on follow-up telephone calls. 69.2% (95% CI 38.6% to 90.9%) (9/13 patients) in the intervention group successfully discontinued or reduced their PPI compared to 7.1% (95% CI 0.2 to 33.9) (1/14 patients) in the control group. The difference between groups was statistically significant (p=0.001).Conclusion and relevanceStatistically significantly more patients discontinued or reduced their use of PPI after counselling by the pharmacy staff. The pharmacy staff is capable of identifying patients for whom PPI dose reduction or discontinuation is relevant and performing a successful counselling on discontinuation or reduction of the use of PPIs.References and/or acknowledgements1. Schepisi R, et al. J Nutr Health Aging 2016;20(6):665–670.2. Akram F, et al. Australas Med J 2014;7(11):465–470.3. Mössner, J. Dtsch Arztebl Int 2016;113:477–483.Conflict of interestNo conflict of interest</description><subject>Conflicts of interest</subject><subject>Counseling</subject><subject>Gastroesophageal reflux</subject><subject>Hospitalization</subject><subject>Neuroendocrine tumors</subject><subject>Pharmacy</subject><subject>Section 4: Clinical pharmacy services</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpFkEtLxDAUhYMoONT5CULAdce8k7qT8QkDCuq6pI_YlLapSbp34x_1l9g6Plb3LM49954PgFOMNhhTcV63zdho36cEEZLWuhk3mToAK4KYTLNMsMM_zcUxWIdgC8QpVRmj2Qq0bPv4lCIuP98_rmwo3RDtMOlo3QCdgaN3cVbj1I_QDo0tbHQ-wGrydniFjQujjbqz4XvhAmro9VC53oa6gkuWd103y-it7k7AkdFdqNc_MwEvN9fP27t093B7v73cpQXGUqWmqrkWUleqpIjwohRUYs40M6Jk0lAjVGFEwTHimBBJGKcVRRJrXXHNjaQJONvnzs-_TXWIeesmP8wncyIkoQKruX8C8N5V9O2_AaN8oZr_Us0XqvlCNc8U_QLBHHBZ</recordid><startdate>20220323</startdate><enddate>20220323</enddate><creator>Nielsen, JL</creator><creator>Sørensen, CA</creator><creator>Stawowy, M</creator><creator>Bonnerup, DK</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20220323</creationdate><title>4CPS-057 Discontinuation of proton pump inhibitors during hospitalisation: a randomised controlled trial</title><author>Nielsen, JL ; Sørensen, CA ; Stawowy, M ; Bonnerup, DK</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1178-fde5a67ad8c3025bc637154a4f6c47f3f68bf6b510512272453d3071aad5a5f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Conflicts of interest</topic><topic>Counseling</topic><topic>Gastroesophageal reflux</topic><topic>Hospitalization</topic><topic>Neuroendocrine tumors</topic><topic>Pharmacy</topic><topic>Section 4: Clinical pharmacy services</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nielsen, JL</creatorcontrib><creatorcontrib>Sørensen, CA</creatorcontrib><creatorcontrib>Stawowy, M</creatorcontrib><creatorcontrib>Bonnerup, DK</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nielsen, JL</au><au>Sørensen, CA</au><au>Stawowy, M</au><au>Bonnerup, DK</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-057 Discontinuation of proton pump inhibitors during hospitalisation: a randomised controlled trial</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><date>2022-03-23</date><risdate>2022</risdate><volume>29</volume><issue>Suppl 1</issue><spage>A46</spage><epage>A47</epage><pages>A46-A47</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and importanceMany patients take proton pump inhibitors (PPIs) even though the drugs are no longer needed.1 2 We know that there are side effects to long-term PPI treatment.3 No previous studies have examined whether it is possible to reduce or discontinue treatment during hospitalisation and continue it successfully after discharge.Aim and objectivesThe aim of the study was to investigate if PPIs can be discontinued or reduced through counselling by pharmacy staff during hospitalisation.Material and methodsA prospective randomised controlled study was performed in the Emergency and Medical Department. Patients were included if they had received PPIs for at least 2 months and were aged 18 years or older.Patients were excluded(1) if they were diagnosed with gastric ulcer within 6 months, eosinophilic oesophagitis, gastroesophageal reflux disease (GERD), Barrett’s oesophagus, gastrinoma and (2) if they were aged over 50 years and on treatment with non-steroidal anti-inflammatory drug (NSAIDs) except low-dose acetylsalicylic acid, steroids and/or platelet inhibitors, anticoagulants.The intervention was performed by pharmacy staff and included counselling on discontinuation or reduction of the use of PPIs, and also included a strategy to cope with rebound symptoms.The primary outcome was the proportion of patients who successfully discontinued or reduced their use of PPIs at follow-up telephone call 30 days after discharge. The data were tested with Fisher’s exact test (small samples).Results31 adults were included; 4 withdrew at their own request or because they could not be reached on follow-up telephone calls. 69.2% (95% CI 38.6% to 90.9%) (9/13 patients) in the intervention group successfully discontinued or reduced their PPI compared to 7.1% (95% CI 0.2 to 33.9) (1/14 patients) in the control group. The difference between groups was statistically significant (p=0.001).Conclusion and relevanceStatistically significantly more patients discontinued or reduced their use of PPI after counselling by the pharmacy staff. The pharmacy staff is capable of identifying patients for whom PPI dose reduction or discontinuation is relevant and performing a successful counselling on discontinuation or reduction of the use of PPIs.References and/or acknowledgements1. Schepisi R, et al. J Nutr Health Aging 2016;20(6):665–670.2. Akram F, et al. Australas Med J 2014;7(11):465–470.3. Mössner, J. Dtsch Arztebl Int 2016;113:477–483.Conflict of interestNo conflict of interest</abstract><cop>London</cop><pub>British Medical Journal Publishing Group</pub><doi>10.1136/ejhpharm-2022-eahp.98</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2022-03, Vol.29 (Suppl 1), p.A46-A47
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2672361853
source PubMed Central; EZB Electronic Journals Library
subjects Conflicts of interest
Counseling
Gastroesophageal reflux
Hospitalization
Neuroendocrine tumors
Pharmacy
Section 4: Clinical pharmacy services
title 4CPS-057 Discontinuation of proton pump inhibitors during hospitalisation: a randomised controlled trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A50%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-057%E2%80%85Discontinuation%20of%20proton%20pump%20inhibitors%20during%20hospitalisation:%20a%20randomised%20controlled%20trial&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Nielsen,%20JL&rft.date=2022-03-23&rft.volume=29&rft.issue=Suppl%201&rft.spage=A46&rft.epage=A47&rft.pages=A46-A47&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2022-eahp.98&rft_dat=%3Cproquest_bmj_j%3E2672361853%3C/proquest_bmj_j%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2672361853&rft_id=info:pmid/&rfr_iscdi=true